Imricor Medical Systems (ASX:IMR): US Commercial Launch and Cardiac MRI Platform Developments

Aditi Sarkar

22 October 2026 04:20 PM AEDT

Imricor Medical Systems (ASX:IMR): US Commercial Launch and Cardiac MRI Platform Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Imricor (ASX:IMR) identified Rady Children’s Hospital-San Diego as its first commercial US customer in September 2026.
FDA clearances in 2026 cover NorthStar and the Vision-MR Diagnostic Catheter, including pediatric uses.
June 2026 quarter-end cash and marketable securities totalled US$67.46 million.
The company reported a June-quarter net loss of US$7.38 million and operating cash outflow of US$6.11 million.

Imricor Medical Systems, Inc. (ASX:IMR) develops magnetic resonance-compatible devices and software for cardiac catheter procedures, allowing clinicians to guide interventions using real-time MRI rather than X-ray fluoroscopy. On 22 October 2026, the company’s ASX security price was AUD 1.335, down 0.74% for the session. Its recent announcements concern US commercial entry, regulatory clearances and partnerships supporting installation of interventional MRI laboratories.

Company Business

The Minnesota-based medical technology company supplies equipment, mapping software and disposable instruments used inside interventional magnetic resonance (iMR) laboratories. Its portfolio includes the NorthStar mapping and guidance system, Vision-MR diagnostic and ablation catheters, and Advantage-MR electrophysiology recording equipment. Imricor (ASX:IMR) has activities in Europe and the United States, with previously announced commercial arrangements in the Middle East.

The commercial model combines one-off capital equipment sales with software licences and consumables tied to clinical procedure volumes. Regulatory permission differs by device and jurisdiction: US clearance of diagnostic products does not constitute approval of the company’s ablation catheter. Adoption also depends on hospital procurement, compatible scanners, clinical training and procedure workflows.

Recent Development

In September 2026, Imricor (ASX:IMR) announced Rady Children’s Hospital-San Diego as its first commercial US hospital customer for Imricor Cardiovascular, a business line introduced in August. The initiative extends use of its imaging and guidance technology beyond electrophysiology to cardiac catheterisation. The announcement signalled the commencement of a US commercial programme rather than evidence of a broad installed customer base.

During August, Imricor and Philips announced a laboratory configuration combining Philips’ 1.5-tesla MRI platform with Imricor devices and workflow technology. Earlier in 2026, US regulators granted 510(k) clearances for NorthStar and the Vision-MR Diagnostic Catheter; July clearances extended both products to pediatric use. These permissions support specified diagnostic applications while the ablation programme follows a separate approval pathway.

Imricor (ASX:IMR) continued its VISABL-AFL clinical investigation for MRI-guided atrial flutter ablation and worked on submissions for additional equipment. Its August investor presentation identified completion of the trial, regulatory decisions and initial US commercial installations as items for subsequent reporting.

Financial Performance and Sector Context

For the June 2026 quarter, Imricor (ASX:IMR) recorded revenue of approximately US$61,000, compared with US$65,000 in the corresponding 2025 quarter. Management attributed limited sales activity partly to customer hospitals undertaking clinical trial procedures. The company reported EBITDA of negative US$7.26 million against negative US$5.27 million in the prior-year quarter. Research and development expenditure increased to US$3.61 million from US$2.79 million.

The quarterly net loss narrowed to US$7.38 million from US$7.80 million, influenced by non-operating accounting movements. Underlying net loss widened to US$7.03 million from US$5.08 million. Net operating cash outflow was US$6.11 million, compared with US$4.56 million a year earlier. These figures are denominated in US dollars, the company’s reporting currency.

At 30 June 2026, cash and cash equivalents were US$60.54 million and marketable securities US$6.92 million, totalling US$67.46 million. Total assets were US$73.59 million and liabilities US$44.52 million. A financing placement contributed to the higher cash balance. For the cardiac device sector, regulatory review, hospital capital budgets and evidence of clinical utility remain important commercialisation factors.

Risks to Consider

Imricor (ASX:IMR) remains exposed to regulatory timing, clinical trial execution and slower-than-planned hospital adoption. Limited current sales relative to operating expenditure make cash consumption significant. Device development, manufacturing scale-up and access to MRI-compatible laboratory infrastructure can also affect deployment. Future revenue depends on converting regulatory clearances and purchase discussions into operational customer programmes.

What to Watch Next

Relevant milestones include results from the VISABL-AFL trial, additional US device submissions and decisions, the commercial progress of Rady Children’s programme, and further NorthStar installations. Updates on recurring software and consumable sales would help distinguish installed capacity from actual clinical usage. Subsequent quarterly reports will show whether operating expenditure and cash outflows change as commercial operations expand.

Key Insights

Imricor (ASX:IMR) entered a new phase of US commercial activity during 2026 following regulatory clearances for diagnostic technology and its first announced US hospital customer. Its June-quarter financial statements nevertheless showed modest revenue, a continuing net loss and material operating cash consumption. Hospital uptake, remaining regulatory approvals, clinical trial progress and liquidity are measurable issues for future disclosure.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.